Bayesian Capital Management’s Novartis NVS Stock Holding History

Bayesian Capital Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$371K	Buy	+2,365	New	+$355K	0.24%	119
2024 Q3	–	Sell	-14,700	Closed	-$1.56M	–	941
2024 Q2	$1.56M	Buy	14,700 +4,100	+39%	+$412K	0.18%	152
2024 Q1	$1.03M	Buy	+10,600	New	+$1.09M	0.1%	281
2023 Q2	–	Sell	-16,793	Closed	-$1.54M	–	985
2023 Q1	$1.54M	Sell	16,793 -19,800	-54%	-$1.73M	0.19%	157
2022 Q4	$3.32M	Buy	36,593 +9,600	+36%	+$809K	0.49%	21
2022 Q3	$2.05M	Buy	+26,993	New	+$2.24M	0.42%	46
2022 Q2	–	Sell	-16,617	Closed	-$1.46M	–	988
2022 Q1	$1.46M	Buy	+16,617	New	+$1.44M	0.22%	126
2020 Q4	–	Sell	-7,213	Closed	-$627K	–	614
2020 Q3	$627K	Buy	+7,213	New	+$625K	0.15%	176
2020 Q1	–	Sell	-6,998	Closed	-$663K	–	920
2019 Q4	$663K	Sell	6,998 -20,600	-75%	-$1.85M	0.11%	241
2019 Q3	$2.4M	Buy	27,598 +22,300	+421%	+$2M	0.45%	47
2019 Q2	$484K	Buy	+5,298	New	+$448K	0.1%	272
2019 Q1	–	Sell	-5,022	Closed	-$386K	–	695
2018 Q4	$386K	Buy	+5,022	New	+$391K	0.08%	346
2018 Q3	–	Sell	-12,066	Closed	-$817K	–	752
2018 Q2	$817K	Sell	12,066 -11,623	-49%	-$802K	0.18%	148
2018 Q1	$1.72M	Buy	+23,689	New	+$1.8M	0.44%	34
2017 Q4	–	Sell	-14,650	Closed	-$1.13M	–	670
2017 Q3	$1.13M	Buy	14,650 +10,156	+226%	+$767K	0.27%	118
2017 Q2	$336K	Buy	+4,494	New	+$319K	0.12%	257

Other funds holding NVS

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bayesian Capital Management's NVS Position: Q2 2026 in Review

Bayesian Capital Management opened a new position in Novartis (NVS) in Q2 2026: 2,365 shares worth $371K. The stake represents 0.24% of the portfolio and ranks #119 among its holdings. This is a return to the name: Bayesian Capital Management previously reported a position in NVS as recently as Q2 2024.

Bayesian Capital Management first reported a position in NVS in Q2 2017 and has held it in 16 quarters since. The position peaked at $3.32M in Q4 2022. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

Bayesian Capital Management held 2,365 shares of Novartis worth $371K as of Q2 2026.
Novartis was a new Bayesian Capital Management position in Q2 2026.
Novartis made up 0.24% of Bayesian Capital Management's portfolio in Q2 2026, its #119 holding.
Bayesian Capital Management first reported a position in Novartis in Q2 2017 and has held it in 16 quarters since.
Bayesian Capital Management's Novartis position peaked at $3.32M in Q4 2022.
1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.